Chemical structure of nelfinavir
Find information on thousands of medical conditions and prescription drugs.

Viracept


Nelfinavir (Viracept®) is an antitretroviral drug used in the treatment of the human immunodeficiency virus (HIV). Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is generally used in combination with other antiretroviral drugs; the other major group of antiretrovirals is the reverse transcriptase inhibitors. Nelfinavir is presented as the mesilate (mesylate) ester prodrug. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

History

Nelfinavir was developed by Agouron Pharmaceuticals, at the time a division of Japan Tobacco but now a subsidiary of Pfizer. It was granted FDA approval for therapeutic use in 1997. Agouron's patent on the drug will expire in 2014.

Mode of action

Nelfinavir is a protease inhibitor: it inhibits HIV-1 and HIV-2 proteases. This protease is an enzyme which cleaves viral protein molecules into smaller fragments, and it is vital for both the replication of the virus within the cell and also the release of mature viral particles from an infected cell. Though this mode of action is common to all protease inhibitors, the precise mode of binding of nelfinavir to the enzyme may be sufficiently unique to reduce cross-resistance between it and other PIs. Also, not all PIs inhibit both HIV-1 and HIV-2 proteases.

Toxicity

Nelfinavir can produce a range of adverse effects. Common (experienced by more than one in one hundred patients; greater than 1%) are flatulence, diarrhoea or abdominal pain. Infrequent (experienced by one in one thousand to one in one hundred patients; 0.01 - 0.1%) adverse effects are fatigue, rash, mouth ulcers or hepatitis. Rarely (less than one in one thousand patients; under 0.01%) nephrolithiasis, arthralgia, leucopenia, pancreatitis or allergic reactions may occur.

Interactions

Nelfinavir's interaction profile is similar to that of other protease inhibitors. Most interactions occur at the level of the Cytochrome P450 isozyme 3A4, by which nelfinavir is metabolised.

Read more at Wikipedia.org


[List your site here Free!]



Viracept - Jet eye: focus on new products, hot happenings and cool promotions nationwide! - Brief Article
Viracept should be used in combination with other HIV medications for the treatment of HIV. Think ahead, talk to your doctor, and plan your future with ...
NELFINAVIR - Viracept
Nelfinavir is supplied in light blue, film-coated, Capsule-shaped tablets imprinted with "VIRACEPT" on one side and "250 mg" on the other. Nelfinavir ...
Ten years of HAART
The year 1996 has brought a sea change in AIDS research and treatment. Three major factors have contributed to this sea change: a new understanding of viral pathogenesis, new and powerful antiretro
Therapeutic and diagnostic advances in the HAART era
It has been almost 10 years since the approval of the first protease inhibitor, saquinavir (Invirase) in December 1995. Since that time, there have been great advances in treatment monitoring, trea
HAART at 10—a CFA timeline
Please note: the events and trends listed on this timeline are by year only and are not listed in any particular order within each year. The sources ...
Eszopiclone for treatment of transient and chronic insomnia
Synopsis Eszopiclone (Lunesta), a nonbenzodiazepine hypnotic agent, is indicated for the treatment of transient and chronic insomnia. Its mechanism ...
HIV drug approvals increase options for adults, children - protease inhibitor Viracept is approved for HIV-infected children and adults - Brief Article
A new protease inhibitor for treating HIV infection--not only in adults but children, as well--has been approved by FDA. In addition, the agency has ...
Pharmaco-fakery
We've been hearing a lot about counterfeit drugs this month, from thought-provoking sessions at the American Association of Pharmaceutical Scientists' ...

Home Contact Resources Exchange Links ebay